Editas Medicine Q4 2025 net loss $5.6M; EDIT-401 IND on track mid-2026

Editas Medicine, Inc.

Cash $146.6M at Dec 31, 2025, down from $269.9M; runway into Q3 2027.
Net loss Q4 2025 $5.6M ($0.06/sh) vs $45.4M ($0.55/sh) in Q4 2024.
Full year 2025 net loss $160.1M ($1.80/sh) vs $237.1M ($2.88/sh) in 2024.
Lead candidate EDIT-401 achieved >90% mean LDL-C reduction in preclinical; IND/CTA submission expected by mid-2026.
First-in-human trial in HeFH planned for 2026; early proof-of-concept data targeted by year-end 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Editas Medicine, Inc. reported financial results for the fourth quarter and full year 2025.

Period: the fourth quarter and full year 2025
Result: reported results

Exact text from the filing

On March 9, 2026 , Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter and year ended December 31, 2025 and other business highlights.

View on SEC.gov

Browse all earnings releases →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001650664-26-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.